Palvella Therapeutics (PVLA) Notes Payables (2024 - 2025)
Palvella Therapeutics (PVLA) posted quarterly Notes Payables of $2.2 million for Q4 2025, up 11.02% year-over-year from $2.0 million in Q4 2024, and down 0.9% quarter-over-quarter from $2.2 million in Q3 2025.
Palvella Therapeutics (PVLA) Notes Payables (2024 - 2025) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Notes Payables for 2 consecutive years, with $2.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Notes Payables rose 11.02% year-over-year to $2.2 million; the TTM figure through Dec 2025 stood at $2.2 million (up 11.02% YoY), while the FY2025 annual figure was $2.2 million, up 11.02% from the prior year.
- Notes Payables slipped to $2.2 million in Q4 2025 per PVLA's latest filing, from $2.2 million in the prior quarter.
- Across five years, Notes Payables topped out at $2.2 million in Q3 2025 and bottomed at $2.0 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.20 Mn |
| Sep 30, 2025 | 2.22 Mn |
| Jun 30, 2025 | 1.98 Mn |
| Mar 31, 2025 | 1.98 Mn |
| Dec 31, 2024 | 1.98 Mn |